Skip to main content

WVU Buys Affy System for $300K; Plans Work on Diabetes, Stroke, Brain Disorders

NEW YORK, April 18 (GenomeWeb News) - The University of West Virginia has invested $300,000 on a microarray platform from Affymetrix, according to a local news report.


The Dominion Post in Morgantown, WV, reported last week that WVU recently purchased the system with the intent of studying diabetes, strokes, and brain disorders. The equipment was funded by the National Institutes of Health, the WVU Health Sciences Strategic Research Plan and private donations to the WVU Eye Institute, the report stated.

Sepideh Zareparsi, an assistant professor at the WVU Eye Institute, said she will use the platform to research diabetic retinopathy, which is known to cause blindness.

Thomas Saba, associate vice president for WVU health sciences' research and graduate studies outlined some areas of interest at WVU, noting that West Virginiansare prone to several conditions that have a genetic component, including diabetes, obesity, stroke, and diseases of the brain and nervous system, the report stated.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.